Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Yun O. Long"'
Autor:
Badry Bursulaya, Yun O. Long, Jaganmohan Anumolu, Matthew McNeill, Sangamesh Badiger, Rina Fong, Michael DiDonato, Mari Manuia, Jie Li, Bender Steven Lee, Jose Juarez, Wenshuo Lu, Gerald Lelais, Daniel E. Mason, Thomas H. Marsilje, John Isbell, Kevin Johnson, Shailaja Kasibhatla, Bei Chen, Glen Spraggon, Pierre-Yves Michellys, Todd Groessl, Robert Epple, Yong Jia, Perry Gordon, Chun Li
Publikováno v:
Journal of Medicinal Chemistry. 59:6671-6689
Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR. However, both resistance through a secondary T790M mutation at the gatekeeper residue a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26a973c726b34b81320ef338d4a330d6
https://doi.org/10.1021/acs.jmedchem.5b01985
https://doi.org/10.1021/acs.jmedchem.5b01985
Autor:
Gérald, Lelais, Robert, Epple, Thomas H, Marsilje, Yun O, Long, Matthew, McNeill, Bei, Chen, Wenshuo, Lu, Jaganmohan, Anumolu, Sangamesh, Badiger, Badry, Bursulaya, Michael, DiDonato, Rina, Fong, Jose, Juarez, Jie, Li, Mari, Manuia, Daniel E, Mason, Perry, Gordon, Todd, Groessl, Kevin, Johnson, Yong, Jia, Shailaja, Kasibhatla, Chun, Li, John, Isbell, Glen, Spraggon, Steven, Bender, Pierre-Yves, Michellys
Publikováno v:
Journal of medicinal chemistry. 59(14)
Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR. However, both resistance through a secondary T790M mutation at the gatekeeper residue a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e6581993755c96201e35fb6c7ecb996e
https://pubmed.ncbi.nlm.nih.gov/27433829
https://pubmed.ncbi.nlm.nih.gov/27433829
Autor:
Jeff Kucharski, Ulf Peters, Yun O. Long, Shisheng Li, Pingda Ren, Ata Zarieh, Dana D. Hu-Lowe, Ke Yu, Yuan Liu, Tao Wu, Carol Thach, Dirk Brehmer, Tess Ely, Xin Guo, Patrick P. Zarrinkar, Matthew P. Patricelli, Yi Wang, Rasmus Hansen, Dashyant Dhanak, Yi Liu, Jun Feng, Shuangwei Li, Matthew R. Janes, Yuching Chen, Sarah J. Firdaus, Levan Darjania, Linda Kessler, Jeffrey H. Chen, Xiaohu Deng, Yvonne Yao, Anjali Babbar, Matthew V. Lorenzi, Jingchuan Zhang, Lian-Sheng Li
Publikováno v:
Cell. 172:578-589.e17
KRASG12C was recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in vicinity to an inducible allosteric switch II pocket (S-IIP). Success of this approach requires active cycling of KRASG12C between its act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cd2f7a70c8f8bca445016883561281f
https://doi.org/10.1016/j.cell.2018.01.006
https://doi.org/10.1016/j.cell.2018.01.006